Objective: Antipsychotic use is associated with elevated cardiometabolic risk. Guidelines for
metabolic risk screening of individuals taking antipsychotics have been issued, but with little …

Premature mortality in people living with a severe mental illness (SMI) is often attributed to
multiple factors including the use of medicines such as antipsychotics. Second-generation …

BACKGROUND: Monitoring protocols have been developed because patients taking
atypical antipsychotics are more prone to developing metabolic syndrome, which leads to …

Introduction Patients with severe mental illness (SMI) have poor physical wellbeing, leading
essentially shorter lives, compared with the general population. Routine metabolic …

Background Compliance with guidelines regarding monitoring of metabolic adverse effects
induced by antipsychotics has been consistently low. We characterised and evaluated the …

The objectives of this study were to identify the risk factors for metabolic syndrome in
patients on antipsychotics and to compare the frequency of metabolic monitoring with …

INTRODUCTION: Patients diagnosed with a chronic mental illness have a 2 to 3 times
higher likelihood of developing metabolic abnormalities than their non–mentally ill …

Background Despite their known effectiveness, antipsychotics possess significant
cardiometabolic adverse event profiles. Guidelines emphasise routine monitoring, however …

Background: Metabolic syndrome (MS) is associated with greater risk of morbimortality and it
has high prevalence in people with mental illness. Objective: Estimate the prevalence of …

Objectives This study aims to determine the proportion of initial cardiometabolic assessment
and its predicting factors in adults with schizophrenia, bipolar disorder or other related …